Table 4 Summary of the primary outcomes, weighted medians and outcomes with highest ranked weighted medians for the 25 nephrology trial primary outcomes. The six trials marked [**Primary outcome match**] are those where the primary outcome was either considered most important by the panel or was among those considered equally most important by the panel

Trial 1 [**Primary outcome match**]

End-stage renal disease or death from cardiovascular causes

11

4

1 [1-4]

11

End-stage renal disease or death from cardiovascular causes

1 [1-4]

  HCPs

5

1 [1-3]

4

1 [1-3]

  Patients

6

1.5 [1-4]

6

1.5 [1-4]

Trial 2

Mean change from the baseline haemoglobin level to the mean level during the evaluation period

11

3

2 [1-3]

11

Mean change from the baseline haemoglobin level to the mean level during the evaluation period

Proportion of patients in whom there was a response in haemoglobin levels

Proportion of patients receiving a transfusion

2 [1-3]

2 [1-3]

2 [1-3]

  HCPs

6

2 [1-3]

6

Mean change from the baseline haemoglobin level to the mean level during the evaluation period

1 [1-3]

Patients

5

1 [1-3]

4

1) Mean change from the baseline haemoglobin level to the mean level during the evaluation period

2) Proportion of patients in whom there was a response in haemoglobin levels 3) Proportion of patients receiving a transfusion

2 [1-3]

2 [1-3]

2 [1-3]

Trial 3

Occurrence of a major cardiovascular or renal event

10

9

4 [1-9]

8

1) Occurrence of a major cardiovascular or renal event

2) Need for dialysis or transplantation

3) Worsening of kidney function

4 [1-9]

4 [1-6]

4 [1-9]

  HCPs

5

3 [1-5]

5

All-cause mortality

1 [1-6]

  Patients

5

4 [3-9]

3

Need for dialysis or transplantation

1 [1-6]

Trial 4

Difference between treatment groups in the proportion of patients remaining on spironolactone at week 12

11

7

5 [1-7]

6

Difference between treatment groups in the change in systolic automated office blood pressure from baseline to week 12

2 [1-7]

  HCPs

5

5 [1-6]

3

Difference between treatment groups in the change in systolic automated office blood pressure from baseline to week 12

2 [1-5]

  Patients

6

5.5 [2-7]

3

Patient-reported outcomes as measured by the EQ-5D-5L questionnaire

1.5 [1-7]

Trial 5

Independence from dialysis at 90 days after random allocation to groups

10

5

3.5 [1-5]

10

Overall survival at the end of the study

1 [1-5]

  HCPs

5

3 [1-4]

5

Overall survival at the end of the study

1 [1-5]

  Patients

5

4 [1-5]

5

Overall survival at the end of the study

1 [1-5]

Trial 6 [**Primary outcome match**]

A composite of death from any cause by 28 days after randomisation and the presence of at least one organ failure at 7 days after randomization

10

7

1 [1-3]

10

A composite of death from any cause by 28 days after randomisation and the presence of at least one organ failure at 7 days after randomization

1 [1-3]

  HCPs

5

1 [1-1]

5

A composite of death from any cause by 28 days after randomisation and the presence of at least one organ failure at 7 days after randomization

1 [1-1]

  Patients

5

2 [1-3]

5

A composite of death from any cause by 28 days after randomisation and the presence of at least one organ failure at 7 days after randomization

2 [1-3]

Trial 7

A ranking of clinical outcomes, maximum relative change in creatinine, dialysis, and death, within 7 days of randomization

10

6

2.5 [1-5]

10

Death

2 [1-6]

  HCPs

5

2 [2-5]

5

Death

1 [1-4]

  Patients

5

3 [1-5]

5

Progression to higher stages of acute kidney injury

2 [1-6]

Trial 8 [**Primary outcome match**]

A further 20% decline in excretory renal function from baseline readings

10

3

1 [1-2]

10

A further 20% decline in excretory renal function from baseline readings

1 [1-2]

  HCPs

5

1 [1-2]

5

A further 20% decline in excretory renal function from baseline readings

1 [1-2]

  Patients

5

1 [1-1]

5

A further 20% decline in excretory renal function from baseline readings

1 [1-1]

Trial 9

Relapse-free survival based on the period of time until the first relapse

10

3

2 [1-3]

10

Relapse-free survival based on the period of time until the first relapse

Probability of progression-free survival based on the time until the progression to FRNS, SDNS or SRN

Relapse rate

2 [1-3]

2 [1-3]

2 [1-3]

  HCPs

5

2 [1-3]

5

Probability of progression-free survival based on the time until the progression to FRNS, SDNS or SRN

1 [1-3]

  Patients

5

1 [1-3]

5

Relapse-free survival based on the period of time until the first relapse

1 [1-3]

Trial 10

The change in UACR from baseline to the end of treatment

10

10

4 [2-9]

7

Proportion of participants in remission defined as a reversal of UACR to normoalbuminuria

3 [1-8]

  HCPs

5

4 [2-6]

4

Proportion of participants in remission defined as a reversal of UACR to normoalbuminuria

Proportion of participants who sustained remission after treatment

2 [1-8]

2 [1-5]

  Patients

5

5 [2-9]

3

Plasma aldosterone concentration

2 [2-7]

Trial 11

The change in log-transformed urine albumin-to-creatinine ratio from baseline to the end of treatment

10

9

3.5 [1-8]

9

eGFR

The remission rate from early-stage nephropathy to prenephropathy stage at the end of treatment

2 [1-6]

2 [1-6]

  HCPs

5

3 [1-4]

5

The progression rate from early-stage nephropathy to overt nephropathy during the treatment period

2 [1-3]

  Patients

5

5 [3-8]

4

eGFR

1 [1-2]

Trial 12 [**Primary outcome match**]

Percentage of patients with treatment success

10

5

1 [1-5]

10

Percentage of patients with treatment success

1 [1-5]

  HCPs

5

1 [1-5]

5

Percentage of patients with treatment success

1 [1-5]

  Patients

5

1 [1-5]

5

Percentage of patients with treatment success

1 [1,2,3,4,5]

Trial 13

Change in cGFR from baseline to month 12

10

7

3 [2-7]

9

Patient and graft survival

1 [1-4]

  HCPs

5

3 [2-3]

5

Patient and graft survival

1 [1-1]

  Patients

5

4 [3-7]

4

Incidence of AR

1 [1-4]

Trial 14

The rate of haemodialysis independence at 3 months after randomization

10

10

7 [1-10]

3

Overall survival

1.5 [1-7]

  HCPs

5

7 [1-8]

Overall survival

1 [1-5]

  Patients

5

8 [4-10]

Overall survival

2 [1-7]

Trial 15: primary 1 [**Primary outcome match**]

Loss of kidney function at 1 year

12

2

1 [1-2]

12

Loss of kidney function at 1 year

1 [1-2]

  HCPs

5

1 [1-1]

5

Loss of kidney function at 1 year

1 [1-1]

  Patients

7

2 [1-2]

7

Acute kidney injury within 30 days of surgery

1 [1-2]

Trial 15: primary 2

Acute kidney injury within 30 days of surgery

12

2

2 [1-2]

12

Loss of kidney function at 1 year

1 [1-2]

  HCPs

5

2 [2-2]

5

Loss of kidney function at 1 year

1 [1-1]

  Patients

7

1 [1-2]

7

Acute kidney injury within 30 days of surgery

1 [1-2]

Trial 16

eGFR over time

12

8

3 [1-8]

10

Blood pressure control

2.5 [1-8]

  HCPs

5

4 [1-8]

4

Blood pressure control

2 [1-3]

  Patients

7

3 [1-8]

6

Early recognition and diagnosis of CKD

2 [1-6]

Trial 17

Change from baseline to 24 weeks in UACR in the first morning urine sample

11

8

4 [1-7]

9

Serum cystatin C-derived eGFR

3 [1-8]

  HCPs

5

1 [1-5]

5

Change from baseline to 24 weeks in UACR in the first morning urine sample

1 [1-5]

  Patients

6

4.5 [2-7]

4

24-h total urine albumin excretion

2.5 [1-4]

Trial 18

Relative change in serum phosphate concentrations from baseline to end of treatment

12

3

1.5 [1-2]

12

Relative change in serum phosphate concentrations from baseline to end of treatment

1.5 [1-2]

  HCPs

5

1 [1-2]

5

Relative change in serum phosphate concentrations from baseline to end of treatment

1 [1-2]

  Patients

7

2 [1-2]

7

Changes in corrected PTH concentrations from baseline to end of treatment

Relative change in serum phosphate concentrations from baseline to end of treatment

2 [1-3]

2 [1-2]

Trial 19

Mean change in Hgb from baseline to end of treatment

12

4

1.5 [1-4]

12

Mean change in Hgb from baseline to end of treatment

1.5 [1-4]

  HCPs

5

1 [1-1]

5

Mean change in Hgb from baseline to end of treatment

1 [1-1]

  Patients

7

3 [1-4]

7

Mean intradialytic change from pre-haemodialysis to post-haemodialysis in serum iron, unsaturated iron-binding capacity (UIBC) and TSAT

Mean change in Hgb from baseline every 4 weeks

2 [1-4]

2 [1-4]

Trial 20

Measured GFR at 12 months

9

10

4 [1-9]

6

Rate of change of eGFR calculated from creatinine values at 0, 1, 3, 6, 9 and 12 months

1 [1-5]

  HCPs

5

4 [1-9]

4

Rate of change of eGFR calculated from creatinine values at 0, 1, 3, 6, 9 and 12 months

2 [1-5]

  Patients

4

5 [3-9]

2

Rate of change of eGFR calculated from creatinine values at 0, 1, 3, 6, 9 and 12 months

1 [1-1]

Trial 21

Left ventricular mass index

9

10

5 [1-7]

5

All-cause mortality and hospitalization for CV events

1 [1-2]

  HCPs

5 [4-7]

3

All-cause mortality and hospitalization for CV events

1 [1-2]

  Patients

5 [1-7]

2

1)

2) All-cause mortality and hospitalization for CV events Exercise capacity: New York Heart Association functional class, 6-min walk test

2 [1-2]

2 [1-7]

Trial 22

Percentage of subjects achieving an increase in Hb of ≥ 1.0 g/dL at any study point between baseline and End of Study or introduction or dose increase of ESA, blood transfusion or use of iron outside of protocol

9

5

3 [2-5]

5

1)

2) Mean change in Hb from baseline to end of week 6 (day 42) and end of week 8 (day 56)/end of study

Percent of subjects achieving a clinical response

2 [1-5]

2 [1-5]

  HCPs

5

3 [2-4]

5

Percent of subjects achieving a clinical response

1 [1-3]

  Patients

4

3.5 [3-5]

4

Mean change from baseline to highest Hb

1 [1-4]

Trial 23

Rate of s-K + decline in the first 48 h, using all post-baseline s-K + data

9

5

2 [1-3]

9

Rate of s-K + decline in the first 48 h, using all postbaseline s-K + data

Kidney function parameters

2 [1-3]

2 [1-4]

  HCPs

5

2 [1-3]

5

Rate of s-K + decline in the first 48 h, using all postbaseline s-K + data

Changes in s-K + at various time points after start of treatment

2 [1-3]

2 [1-3]

  Patients

4

3 [2-3]

4

Kidney function parameters

1 [1-1]

Trial 24

Proportion of CRR (complete renal remission) at 24 weeks

9

2

2 [1-2]

9

CRR rate at 48 weeks

1 [1-2]

  HCPs

5

2 [1-2]

5

CRR rate at 48 weeks

1 [1-2]

  Patients

4

1 [1-2]

4

Proportion of CRR (complete renal remission) at 24 weeks

1 [1-2]